More on Practice Guidelines

From the NYT story:

Three doctors at the National Institutes of Health have sharply criticized Eli Lilly for its efforts to promote the use of Xigris, an expensive treatment for patients with sepsis, an often deadly blood infection.

In an article published yesterday in The New England Journal of Medicine, the doctors wrote that Lilly — the nation’s sixth-largest drug maker — had manipulated treatment guidelines for sepsis patients to promote Xigris at the expense of older, cheaper and equally effective treatments.

Lilly says that it acted appropriately.